Related Experiment Video
Updated: Aug 9, 2026
07:37
Human Ovarian Surface Epithelium Organoids as a Platform to Study Tissue Regeneration
Published on: August 16, 2024
Alpha-lipoic acid modulates ovarian surface epithelial cell growth
E Vig-Varga1, Eric A Benson, Tony L Limbil
1Department of Biochemistry and Molecular Biology, Indiana University School of Medicine and Walther Oncology Institute, Indianapolis, IN 46220, USA. evig@iupui.edu
Gynecologic Oncology
|April 1, 2006
Summary
Alpha-lipoic acid (ALA) selectively inhibits ovarian cancer cell growth by increasing p27(kip1) levels and reducing inflammation. This antioxidant shows promise in targeting malignant ovarian epithelial cells.
Area of Science:
- Oncology
- Cell Biology
- Biochemistry
Background:
- Intracellular redox state critically regulates inflammation, a process linked to tumor progression.
- Restoring redox balance is hypothesized to inhibit inflammation and subsequent tumor development.
- Ovarian surface epithelial cells are investigated for their response to redox modulation.
Purpose of the Study:
- To investigate the effect of alpha-lipoic acid (ALA) on inflammation and cell proliferation.
- To determine ALA's impact on key inflammatory pathways and cell cycle regulators in ovarian cells.
- To assess ALA's selective efficacy against tumorigenic ovarian surface epithelial cells.
Main Methods:
- Ovarian surface epithelial cells (normal and tumorigenic) were isolated.
- Cell proliferation and apoptosis assays were performed to evaluate ALA's effect.
- Western analysis measured p27(kip1) protein levels; NF-kappaB signaling was assessed via reporter constructs.
Main Results:
- ALA selectively inhibited the proliferation of tumorigenic ovarian surface epithelial cells.
- Growth inhibition was linked to increased p27(kip1) half-life, not apoptosis induction.
- ALA inhibited TNFalpha-induced NF-kappaB signaling, impacting a key inflammatory pathway.
Conclusions:
- ALA demonstrates a growth-inhibitory effect on malignant ovarian surface epithelial cells.
- The study confirms the utility of a syngeneic mouse ovarian cancer model.
- ALA's antioxidant and anti-inflammatory properties offer potential therapeutic avenues for ovarian cancer.
Related Concept Videos
01:27Ovarian Cycle
The menstrual cycle includes a critical component known as the ovarian cycle, which undergoes two main phases each month—the follicular phase and the luteal phase. The follicular phase is variable and averaging around 14 days. Ovulation, triggered by a surge in luteinizing hormone (LH), marks the transition between the two phases. The second phase, the luteal phase, is relatively consistent, lasting approximately 14 days, and is marked by the activity of the corpus luteum. While a cycle length...
01:20Folliculogenesis
Folliculogenesis is the development of ovarian follicles, the specialized structures within the ovarian cortex where oogenesis, or egg development, occurs. This process is essential for female reproductive health and begins during fetal development when primordial follicles are formed. Each primordial follicle comprises a primary oocyte in the center, surrounded by a single layer of squamous pre-granulosa cells. These follicles remain dormant in late prophase I of meiosis until triggered by...
02:07Oogenesis
In human women, oogenesis produces one mature egg cell or ovum for every precursor cell that enters meiosis. This process differs in two unique ways from the equivalent procedure of spermatogenesis in males. First, meiotic divisions during oogenesis are asymmetric, meaning that a large oocyte (containing most of the cytoplasm) and minor polar body are produced as a result of meiosis I, and again following meiosis II. Since only oocytes will go on to form embryos if fertilized, this unequal...